MF

MiraeAsset Financial Group

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Description

MiraeAsset Financial Group is an investment firm.

Investor Profile

MiraeAsset Financial Group has backed more than 7 startups, with 2 new investments in the last 12 months alone. The firm has led 1 rounds, about 14% of its total and boasts 3 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series C, Pre Seed rounds (top funding stages).
  • Majority of deals are located in United States, China, Germany.
  • Strong thematic focus on Biotechnology, Life Science, Genetics.

Stage Focus

  • Series B (43%)
  • Series C (43%)
  • Pre Seed (14%)

Country Focus

  • United States (57%)
  • China (29%)
  • Germany (14%)

Industry Focus

  • Biotechnology
  • Life Science
  • Genetics
  • Biopharma
  • Health Care
  • Information Technology
  • Medical
  • Software
  • Therapeutics
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does MiraeAsset Financial Group frequently co-invest with?

Goldman Sachs Asset Management
North America, New York, United States, New York
Co-Investments: 1
Catalio Capital Management
North America, New York, United States, New York
Co-Investments: 1
DC
North America, Illinois, United States, Chicago
Co-Investments: 1
Casdin Capital
North America, New York, United States, New York
Co-Investments: 2
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 2
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 1
Octagon Capital Advisors
North America, New York, United States, New York
Co-Investments: 2
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 2

Which angels does MiraeAsset Financial Group often collaborate with?

Adrian Cheng
Asia, Hong Kong
Shared Deals: 1

What are some of recent deals done by MiraeAsset Financial Group?

Ensoma

Boston, Massachusetts, United States

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

BiotechnologyGeneticsLife ScienceMedicalOncologyTherapeutics
Series UnknownSep 22, 2025
Amount Raised: $53,000,000
Persona AI

Houston, Texas, United States

Persona AI is a robotics company that provides robotic solutions.

Robotics
Pre SeedMay 7, 2025
Amount Raised: $27,000,000
Atalanta Therapeutics

Boston, Massachusetts, United States

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

BiotechnologyHealth CareLife Science
Series BJan 28, 2025
Amount Raised: $97,000,000
Septerna

San Francisco, California, United States

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

BiotechnologyInformation TechnologyMedicalSoftware
Series BJul 11, 2023
Amount Raised: $150,000,000
Abogen Biosciences

Suzhou, Jiangsu, China

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based RNA and DNA therapeutics.

BiotechnologyGeneticsLife Science
Series CNov 29, 2021
Amount Raised: $300,000,000
EpimAb Biotherapeutics

Shanghai, Shanghai, China

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company.

BiopharmaBiotechnologyHealth CareTherapeutics
Series CMar 22, 2021
Amount Raised: $120,000,000
4D Molecular Therapeutics

Emeryville, California, United States

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

BiotechnologyGenetics
Series CJun 16, 2020
Amount Raised: $75,000,000
BioNTech

Mainz, Rheinland-Pfalz, Germany

BioNTech is a biopharmaceutical company that develops cancer therapeutics for infectious diseases.

BiopharmaBiotechnologyLife SciencePharmaceutical
Series BJul 9, 2019
Amount Raised: $325,000,000

Find More Investors Like MiraeAsset Financial Group

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

MiraeAsset Financial Group | Pipeseed